State-owned pharmaceutical company PT Bio Farma has secured a major export contract valued at Rp1.4 trillion (US$89 million) for 2025, covering a range of vaccines including polio, diphtheria, tetanus, and pertussis.
This milestone contract represents nearly half of the state-owned company’s Rp3 trillion export target for the coming year, according to Deputy CEO Soleh Ayubi.
Speaking at the Ministry of State-Owned Enterprises (SOEs) on Friday, Soleh said that the contract was finalized during an international health summit in Brazil last month, attended by the World Health Organization (WHO), UNICEF, and 43 global pharmaceutical companies.
“With this contract, we are already halfway to meeting our export goal for 2025,” Soleh said, emphasizing that the Rp3 trillion target applies exclusively to exports and does not include domestic sales, on Friday, November 1, 2024.
Bio Farma’s vaccines are used globally, benefiting around 700 million children across 153 countries, which underscores its significant role in global health.
The company is committed to improving vaccine quality and ensuring supply chain reliability. In addition, Bio Farma continues research efforts to develop vaccines for other critical diseases, including HIV and tuberculosis.
“Addressing diseases like HIV and tuberculosis is our focus, in collaboration with private partners, the Ministry of State-Owned Enterprises, and the Ministry of Health,” Soleh said.
